Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance
NCT03227926
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Interventions
DRUG:
Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
DIAGNOSTIC_TEST:
Molecular Screening
Sponsor
Fondazione del Piemonte per l'Oncologia